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A dose-escalation study of irinotecan (CPT-11) combined with S-1, an oral dihydropyrimidine dehydrogenase inhibitory
fluoropyrimidine, was performed to determine the maximum-tolerated dose (MTD), recommended dose (RD), dose-limiting
toxicities (DLTs), and objective response rate (RR) in advanced gastric cancer (AGC). S-1 was administered orally at
80mgm
 2day
 1 from day 1 to 14 of a 28-day cycle and CPT-11 was given intravenously on day 1 and 8 at an initial dose of
70mgm
 2day
 1, stepping up to 100mgm
 2. The treatment was repeated every 4 weeks, unless disease progression was observed.
In the phase I portion, the MTD of CPT-11 was presumed to be 100mgm
 2, because 66.6% of patients (two of three) developed
DLTs. All three patients at the initial RD of CPT-11 (90mgm
 2) experienced grade 4 haematological or grade 3 nonhaematological
toxicities at second course, followed by the dose reduction of CPT-11 from the third course. Considering safety and the ability to
continue treatment, the final RD was determined to be 80mgm
 2. In the phase II portion, 42 patients including seven patients in the
final RD phase I portion were evaluated. The median treatment course was five (range: 1–13). The incidences of severe (grade 3–4)
haematological and nonhaematological toxicities were 19 and 10%, respectively, but all were manageable. The RR was 62% (26 of 42,
95% confidence interval: 47.2–76.6%), and the median survival time was 444 days. Our phase I/II trial showed S-1 combined with
CPT-11 is effective for AGC and is well tolerated, with acceptable toxicity.
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Unresectable advanced or recurrent gastric cancer still has a poor
prognosis despite chemotherapy. Many randomised phase III
studies of combination chemotherapy for unresectable advanced
gastric cancer (AGC) resulted in median survival times (MSTs) of
the 5–9.6 months and overall response rates (RRs) of 9–46% in
Western and Asian countries (Webb et al, 1997; Icli et al, 1998;
Vanhoefer et al, 2000; Ross et al, 2002; Ohtsu et al, 2003). The
significant survival advantage of 5-fluorouracil (5-FU)-based
chemotherapy for AGC has been demonstrated, compared with
best supportive care (Murad et al, 1993; Pyrhonen et al, 1995;
Glimelius et al, 1997); however, a standard regimen for AGC has
not yet been established. New anticancer drugs, such as oral
fluoropyrimidines, taxanes, and irinotecan hydrochloride (CPT-
11), have been developed and their antitumour effects against
gastric cancer and good feasibility have been demonstrated
(Futatsuki et al, 1994; Ajani et al, 1998; Sakata et al, 1998;
Graziano et al, 2000; Koizumi et al, 2000).
S-1 is an oral fluorinated pyrimidine that combines tegafur with
two 5-FU-modulating substances, 5-chloro-2,4-dihydroxy pyridine
and potassium oxonate, in a molar ratio of 1:0.4:1 (Shirasaka
et al, 1996). Tegafur is an oral prodrug of 5-FU, which is gradually
converted to 5-FU. 5-chloro-2,4-dihydroxy pyridine is a reversible
inhibitor of dihydropyrimidine dehydrogenase, which catabolises
5-FU, leading to an increase in antitumour activity. Potassium
oxonate is an orotate phosphoribosyltransferase inhibitor and
decreases the incorporation of 5-FU triphosphate into RNA in the
gastrointestinal mucosa. It reduces the incidence and severity of
diarrhoea. According to the Japanese clinical trials of S-1,
80mgm
 2day
 1 was the recommended dose (RD). In phase II
trials of S-1 against unresectable or recurrent gastric cancer, RRs
were 44–49% with a low incidence of severe toxicities (Sakata et al,
1998; Koizumi et al, 2000).
CPT-11 is an inhibitor of DNA topoisomerase I. A Japanese late
phase II study of CPT-11 as a single agent for AGC obtained an RR
of 23% (Futatsuki et al, 1994). Some previous studies suggested a
lack of crossresistance between CPT-11 with fluoropyrimidines
(Houghton et al, 1996; Cao and Rustum, 2000). Combination of
CPT-11 with 5-FU and leucovorin have shown promising activity
not only in metastatic colorectal cancer but also in AGC (Douillard
et al, 2000; Saltz et al, 2000; Assersohn et al 2004; Bouche et al,
2004; Pozzo et al, 2004).
We therefore conducted a phase I/II clinical study of combina-
tion treatment of S-1 with CPT-11. The primary objectives of the
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sphase I study were to estimate the maximum-tolerated dose (MTD)
of CPT-11 in combination with S-1 and to determine the RD for
phase II studies. In the phase II study, we investigated the clinical
activity and the feasibility of this chemotherapy regimen.
PATIENTS AND METHODS
Patients
Before entry, tumour size was determined by chest or gastro-
intestinal X-ray film, endoscopic examination of the upper
gastrointestinal tract, computed tomographic (CT) scan of the
abdomen, barium enema, and bone scintigram. Measurable lesions
were selected according to response evaluation criteria in solid
tumours (RECIST). A complete blood cell count, liver and renal
function test, and urinalysis were performed within 7 days before
entry. The eligibility criteria were as follows: age 20–80 years;
histologically proven unresectable locally advanced or metastatic
gastric adenocarcinoma; no previous chemotherapy or radio-
therapy, adequate organ function, defined as haemoglobin
48gdl
 1, leucocyte count 44000–12000mm
 3, platelet count
4100000mm
 3, serum bilirubin level o1.5mgdl
 1, serum
transaminase (aspartate aminotransferase and alanine aminotrans-
ferase) o100UI
 1, alkaline phosphatase otwice the upper limit of
the normal range (ULN), serum creatinine level less than the ULN;
Eastern Cooperative Oncology performance status 0–1; expected
survival period 43 months; oral intake of medicines is possible;
and written informed consent from the patients. Patients with
symptomatic brain metastases, large ascites, or pleural effusion
were not eligible. This study was approved by the ethics
committees in each institution.
Treatment schedule
The fixed dose of S-1 (Taiho Pharmaceutical Co. Ltd, Tokyo,
Japan) was 80mgm
 2day
 1. Three doses of S-1 were established
according to body surface area (BSA) as follows: BSA o1.25m
2,
80mgday
 1; BSA 1.25–1.5m
2, 100mgday
 1; and BSA X1.5m
2,
120mgday
 1, as described previously (Sakata et al, 1998; Koizumi
et al, 2000). Patients received their assigned dose of S-1 divided in
two, after breakfast and dinner orally. One course of therapy
consisted of S-1 administered for 14 consecutive days. CPT-11
(Irinotecan; Daiichi Pharmaceutical Co. Ltd, Tokyo, Japan) was
diluted in 500ml physiological saline, and administered as a
90min intravenous (i.v.) infusion on days 1 and 8. The starting
dose of CPT-11 was 70mgm
 2 (level 1), which was to be increased
in 10mgm
 2 increments to 100mgm
 2 (level 4), unless the MTD
were achieved. No intrapatient dose escalation was allowed. At
least three patients were treated at each dose level. If one of three
patients at a given dose developed any dose-limiting toxicity
(DLT), three or more patients were entered at the same dose.
Before proceeding to the next dose level, all patients had received
at least one course. This treatment course was repeated every 4
weeks with an allowance for a delay in treatment if toxicity was
observed. The next course was started only for patients whose
biological parameters had been maintained at levels satisfying the
eligibility criteria, except for the leucocyte count (43000mm
 3),
and with no disease progression observed. Prophylactic adminis-
tration of antiemetic medication (5-HT3 antagonist and corticos-
teroid) at standard doses was routinely used when CPT-11 was
administered to prevent nausea and vomiting. The treatment was
repeated unless disease progression or severe toxicity was
observed.
Evaluation
A complete blood cell count, liver and renal function test, and
urinalysis were assessed at least once a week during the first
course, and every other week afterwards. Before each course,
additional examinations were performed to evaluate sites. The
National Cancer Institute common toxicity criteria version 2.0 was
applied to evaluate the toxicity of this therapy during each course.
Dose-limiting toxicities were defined as grade 4 neutropenia, grade
4 thrombocytopenia, any febrile grade 3 or 4 haematological
toxicity, or grade 3 nonhaematological toxicity (except nausea and
vomiting) during the first course. The MTD was defined as the
dose at which 433% patients experienced DLTs during the first
course. Lesions noted at baseline and 1 week after each course were
measured or evaluated by CT. Objective responses were evaluated
according to the RECIST criteria. The survival period was
calculated from the start of treatment to death or the latest
followed-up day. The eligibility and suitability for assessment and
the objective response to the treatment were reviewed extra-
murally.
RESULT
Between January 2001 and December 2003, 51 eligible patients
were entered in this study. The first 16 patients were entered
into the phase I portion and the next 35 patients were entered into
the phase II portion to confirm the toxicities and efficacy at
the RD. All patients were eligible for toxicity evaluation in any
course and objective response evaluations (Table 1). Thirty-one
patients had undergone gastrectomy and none had received
adjuvant chemotherapy after gastrectomy. Histological evaluation
revealed 21 patients to be intestinal type and 30 patients
to be diffuse type. A total of 267 courses were given. The median
number of treatment courses was four (range: 1–16) and five
(range: 1–13) in phase I and II portion, respectively (Table 2).
The median duration of therapy per patient was 161 days (range:
28–637) in phase I portion, and 172 days (range: 28–599)
in phase II portion, respectively. The median number of days until
the start of the second course after completion of scheduled S-1 in
the first course was 14 (range: 14–21 days) among 46 patients who
were treated with two courses or more. Three of the six patients at
level 3 and 4 required more than 14 days interval to start
the second course, although none of 42 patients did in phase II
portion.
Table 1 Patient characteristics
Phase I portion
Phase II portion
Level 1234
CPT-11 (mgm
 2) 70 80 90 100 80
No. of patients 3733 3 5
Age (years)
Median 70 57 58 63 63
Range 68–76 39–73 51–77 21–67 47–79
o6 5 0522 1 8
X6 5 3211 1 7
Sex
F e m a l e 0101 1 3
M a l e 3632 2 2
Pathology
Intestinal 2210 1 6
Diffuse 1523 1 9
Gastrectomy 1522 2 1
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In the phase I portion at level 2, one patient developed grade 3
diarrhoea during the first course, but the other two patients in the
same cohort showed no DLT. An additional four patients were
enrolled for safety evaluation, but overall only one of the total of
seven patients developed a DLT at 80mgm
 2 of CPT-11. As dose
level 4, two of three patients exhibited DLTs in the first course, one
of whom had grade 3 febrile leucopenia and neutropenia, and
grade 4 thrombocytopenia, another had grade 3 nonhaematologi-
cal toxicity (diarrhoea). The frequency of severe haematological
and nonhaematological toxicities increased according to the
increment of the CPT-11 dose (Table 3). Based on these results,
dose level 4 was declared as the MTD, and level 3 should be
declared as the initial RD according to the protocol. However, all
three patients at level 3 experienced grade 4 haematological or
grade 3 nonhaematological toxicities during the second course,
followed by dose reduction of CPT-11 from the third course. The
dose intensity per course of CPT-11 was 86% of planned CPT-11
dose at level 3, compared with 96% at level 2 (Table 2). Thus,
considering the safety and the continuation of the treatment, the
final RD was level 2 dose of 80mgm
 2 in the following phase II
portion.
Safety
In the 42 patients of the phase II portion including seven patients
assigned at level 2 in the phase I portion, the most frequently
observed severe (grades 3 and 4) haematological toxicity was
neutropenia (6 cases, 14%) (Table 3). Frequently observed
nonhaematological toxicities (all events) included nausea (25
cases, 59%), anorexia (23 cases, 55%), and vomiting (16 cases,
38%). In addition, the overall incidence of diarrhoea was 40% (17
out of 42); however, grade 3 or 4 diarrhoea was observed in four
out of 42 (10%), and recovered within seven days (Table 3). During
this study, eight patients received granulocyte colony-stimulating
factor because of neutropenia. Incidences of the worst-grade
toxicities in patients treated with the final RD were none (four
cases, 10%), grade 1 (11 cases, 26%), grade 2 (16 cases, 38%), grade
3 (seven cases, 17%), and grade 4 (four cases, 10%), respectively.
Neither treatment-related death nor delayed severe toxicity was
observed.
Efficacy
All 42 patients including seven patients assigned in phase I portion
were evaluated to determine the RR at the RD. The RR at the RD in
the phase II portion was 62% (26 of 42, 95% confidence interval
(CI): 47.2–76.6%); 11 patients showed stable disease as their best
response, five patients had PD (Table 4). The median time to
progression (TTP) was 195 days (range: 25–684) in the phase II
portion (Figure 1). The median time to response and the median
overall durations of response in 26 responders in phase II portion
were 48 (range: 28–158) and 178 days (range: 66–643),
Table 2 Completed course and dose intensity (DI)
Phase I portion
Phase II portion
a
Level 1 2 3 4
CPT-11 (mgm
 2) 70 80 90 100
n 373 3 4 2
Course
Median 9 4 6 3 5
Range 6–16 1–13 3–7 2–4 1–13
S-1
DI 1120 1120 1120 1089 1099
%DI 100 100 100 97 98
CPT-11
DI 140 155 155 169 151
%DI 100 96 86 84 94
DI¼dose (per m
2) per course.
aIncluding seven patients at level 2 of phase 1 portion.
Table 3 Toxicity incidence
Course
Phase I portion
First course
Phase II portion
a
All courses
CPT-11 (mgm
 2)
No.of patients
70
3
80
7
90
3
100
3
80
42
Toxicity/grade All events Grade 3/4 All events Grade 3/4 All events Grade 3/4 All events Grade 3/4 All events Grade 3/4
Haematological
Leucopenia 1 0 3 0 1 0 3 1 24 5
Neutropenia 0 0 3 0 1 0 3 1 20 6
Anaemia 1 0 0 0 2 0 2 1 20 3
Thrombocytopenia 0 0 0 0 0 0 1 1 5 2
Nonhaematological
Anorexia 3 0 3 0 2 0 2 1 23 4
Nausea 3 0 4 0 2 0 2 1 25 3
Vomiting 0 0 1 0 2 0 1 1 16 2
Diarrhoea 0 0 1 1 1 0 1 1 17 4
aIncluding seven patients at level 2 of phase 1 portion.
Table 4 Response rate
n CR PR SD PD Response (%)
Phase II portion 42 0 26 11 5 62
Lymph nodes 25 0 15 8 2 60
Liver 12 0 7 3 2 58
Peritoneum 13 0 9 2 2 69
Primary 16 0 11 3 2 69
Total 51 1 30 15 5 61
CR¼complete response; PR¼partial response; SD¼stable disease; PD¼progres-
sive disease. Response rate¼number of CR and PR/total number (n).
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five courses of combination therapy. Subgroup analysis according
to tumour lesion and pathological type for the 42 patients in phase
II portion showed that the RR was 58% (seven of 12) for liver
metastasis, 60% (15 of 25) for lymph node metastasis, 69% (nine
of 13) for metastatic peritoneal nodule, and 69% (11 of 16) for
primary lesions (Table 4), and the RR according to pathological
type was 61% (11 of 18) for the intestinal type and 63% (15 of 24)
for the diffuse type. The MST of patients in the phase II portion
was 444 days (range: 54–1029) and 1- and 2-year survival rates
were 61 and 28%, respectively (Figure 2). The median follow-up
time for survival analysis was 736 days.
DISCUSSION
This study was undertaken to determine the RD for a phase II
study of CPT-11 combined with S-1 for metastatic advanced gastric
cancer and to investigate the antitumour effect and feasibility of
this combination. The RD was determined to be 80mgm
 2 of
CPT-11 on day 1 and day 8, and 80mgm
 2 per day of S-1 on days
1–14 of a 28-day cycle. The phase II study using this combination
obtained an RR of 62% (26 of 42), and in particular, the MST of
444 days and the TTP of 195 days for chemotherapy-naı ¨ve patients
were promising. In addition, toxicity was mild and tolerable, and
therapy was administrated on an outpatient basis.
Two late phase II studies of S-1 as a single agent in advanced
gastric cancer in Japan obtained RRs of 44 and 49%, respectively
(Sakata et al, 1998; Koizumi et al, 2000). Combined analysis of the
results of these phase II studies suggested an MST of 244 days,
while toxicities were generally mild. Based on these data, there are
several ongoing combination studies of S-1 with another anti-
cancer agent with a different mechanism of action, aimed at
achieving more survival benefit.
CPT-11 was shown to lack crossresistance with fluoropyrimi-
dines in both experimental and clinical settings (Vanhoefer et al,
2001). The response rate of CPT-11 alone in gastric cancer was
23% in a Japanese phase II study (Futatsuki et al, 1994). The
response rate in patients with previous 5-FU-containing regimens
was 18.9%, which indicated a lack of crossresistance between
CPT-11 and 5-FU in gastric cancer. Preclinical studies of human
cancer cell lines and tumour xenografts have suggested that
the combination of CPT-11 and 5-FU has additive-to-synergistic
antitumour activities (Houghton et al, 1996). Thus, we selected
CPT-11 as the combination agent to be used with S-1.
When CPT-11 is combined with S-1, there is concern about the
increase of the frequency of severe diarrhoea, which is the
common toxicity not only in CPT-11 alone regimen but also in S-1
alone regimen. As the median time to deteriorate into the worst
grade of S-1-induced diarrhoea was 15 days of consecutive S-1-
alone administration (Nagashima et al, 2005), we planned that
CPT-11 was administrated i.v. on day 1 and day 8, and S-1 was
orally taken for 2 consecutive weeks followed by 2-week drug
holiday. In this phase I portion, S-1 was given at a fixed dose of
80mgm
 2day
 1 and the CPT-11 dose was escalated from
70mgm
 2 as level 1 to 100mgm
 2 as level 4. DLTs were observed
in two of three patients at level 4, which was defined as the MTD.
DLTs consisted of grade 3 febrile neutropenia, grade 4 thrombo-
cytopenia, and grade 3 diarrhoea. According to the protocol
conditions, the initial RD of CPT-11 combined with S-1 should be
the level 3 dose of 90mgm
 2; however, all three patients assigned
the level 3 dose experienced grade 4 haematological or grade 3
nonhaematological toxicities in the second course. Considering the
safety and the ability to continue treatment, the final RD of CPT-11
was the level 2 dose of 80mgm
 2. In the phase II portion, the
incidence of the most common toxicities (grade 3 or 4) was 14%
for neutropenia, and 10% for diarrhoea and anorexia. Thus, mild
and tolerable toxicities resulted in the median treatment course of
5, achieving an RR of 62 and MST of 444 days.
Three other phase I studies for combination therapy with
CPT-11 and S-1 have been reported. Yamada et al (2003) reported
an RD of 150mgm
 2 CPT-11 administration on day 1 with
80mgm
 2day
 1 S-1 administration from day 1 to day 14 of a 21-
day cycle. Another study assigned patients to receive 80mgm
 2
CPT-11 on days 1 and 15, and S-1 from day 1 to day 21, followed
by a 2-week rest (Takiuchi et al, 2005). In the two regimens, the
doses of S-1 were similar to single-agent therapy of S-1, which
consist of 4-week consecutive administration with a 2-week rest.
On the other hand, Komatsu et al (2005) reported the regimen
of 125mgm
 2 CPT-11 on day 1 and day 15, combined with
80mgm
 2day
 1 S-1 administration from day 1 to day 14 of a 28-
day cycle. The dose intensity of S-1 in that regimen, as in ours, is
smaller than that of the single-agent S-1 therapy. Little con-
structive information can be obtained by comparing the results of
these different studies. However, we are the first to report the
promising result of the phase II portion for combination therapy
with CPT-11 and S-1, in detail.
Previous reports indicated that 5-FU might inhibit the conver-
sion of CPT-11 to SN-38, which is its active form (Sasaki et al,
1994; Falcone et al, 2001). On the contrary, it has been reported
that pharmacokinetic (PK) analysis of CPT-11 when combined
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Figure 1 Time to progression curve for the 42 patients in the phase II
portion; the median TTP was 195 days (range: 25–684 days).
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Figure 2 Cumulative overall survival for the 42 patients in the phase II
portion. The median survival time was 444 days (range: 54–1029 days).
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the expected values for CPT-11 as a single agent (Yamada et al,
2003). Additionally, the PK results of S-1 combined with CPT-11
were similar to those obtained by S-1 single-agent treatment
(Takiuchi et al, 2005). Taken together with these data, it appears
there is no PK interaction between CPT-11 and S-1.
Cisplatin has been employed in the treatment of AGC. Boku et al
(1999) reported the promising results of 48% RR and 322 days
MST for AGC treated by CPT-11 combined with CDDP, with
acceptable toxicity. A phase I/II study of S-1 combined with CDDP
indicated the surprising results of an RR of 74% (Koizumi et al,
2003). However, the MST of S-1 combined with CDDP was 383
days, which was shorter than the 444 days in our study. The
incidence of grade 3 or 4 haematological toxicities was almost the
same (16 and 19% in the CDDP combination and CPT-11 combi-
nation, respectively), whereas the incidence of nonhaematological
toxicities was 26% in S-1 combined with CDDP, which was higher
than the 10% in our study. Additionally, in the combination of
CDDP, it is necessary to hydrate patients with drip infusion to
avoid of CDDP-induced renal damages. Thus, S-1 combined with
CPT-11 might be less toxic and more easily manageable in
outpatient clinics than the CDDP-combined regimens.
In three randomised phase II trials, the combination of CPT-11
and 5-FU/LV was compared with the combination of CPT-11 and
CDDP (Pozzo et al, 2004), CDDP and 5-FU/LV (Bouche et al,
2004), and etoposide and 5-FU/LV (ELF) (Moehler et al, 2005). All
three trials indicated that the combination of CPT-11 and 5-FU/LV
was the most effective combination and will be assessed in a phase
III trails. The RR, TTP, and MST in the combination arm of CPT-
11 and 5-FU/LV ranged from 30 to 40%, 4.5–6.9 months, and
10.8–11.3 months, respectively, with acceptable toxicity profiles.
In addition, the randomised phase III study confirmed that the
combination of CPT-11 and 5-FU/LV is superior in terms of TTP,
compared with the combination of CPT-11 and CDDP (Dank et al,
2005). These results underline the potential role of the combina-
tion of CPT-11 and 5-FU/LV. If S-1 could be used instead of 5-FU
infusion, S-1 combined with CPT-11 might become an alternative
to the combination of CPT-11 and 5-FU/LV. We are awaiting the
results of a randomised phase III trial (5-FU infusion vs S-1 vs
CPT-1 with CDDP) for AGC patients.
In conclusion, our phase I/II trial showed S-1 combined with
CPT-11 is effective and well tolerated with acceptable toxicity. This
regimen should be one of the choices for an experimental arm in
phase III trials in near future.
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